User profiles for Terrance G. Johns
 | Terrance G JohnsTelethon Kids Institute Verified email at telethonkids.org.au Cited by 10141 |
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Human solid tumors frequently have pronounced heterogeneity of both neoplastic and
normal cells on the histological, genetic, and gene expression levels. While current efforts are …
normal cells on the histological, genetic, and gene expression levels. While current efforts are …
Targeting the ERBB family in cancer: couples therapy
N Tebbutt, MW Pedersen, TG Johns - Nature Reviews Cancer, 2013 - nature.com
The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many
types of solid tumour. Various therapeutics targeting these receptors have been approved …
types of solid tumour. Various therapeutics targeting these receptors have been approved …
The epidermal growth factor receptor variant III (EGFR v III): where wild things are altered
HK Gan, AN Cvrljevic, TG Johns - The FEBS journal, 2013 - Wiley Online Library
The epidermal growth factor receptor ( EGFR ) is overexpressed in a variety of human
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …
The structure and function of myelin oligodendrocyte glycoprotein
TG Johns, CCA Bernard - Journal of neurochemistry, 1999 - Wiley Online Library
: Myelin oligodendrocyte glycoprotein (MOG) is a quantitatively minor component of CNS
myelin whose function remains relatively unknown. As MOG is an autoantigen capable of …
myelin whose function remains relatively unknown. As MOG is an autoantigen capable of …
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
…, AW Burgess, EW Hoffman, TG Johns… - Proceedings of the …, 2007 - National Acad Sciences
An array of cell-surface antigens expressed by human cancers have been identified as
targets for antibody-based therapies. The great majority of these antibodies do not have …
targets for antibody-based therapies. The great majority of these antibodies do not have …
[HTML][HTML] Targeted drug delivery using genetically engineered diatom biosilica
The ability to selectively kill cancerous cell populations while leaving healthy cells unaffected
is a key goal in anticancer therapeutics. The use of nanoporous silica-based materials as …
is a key goal in anticancer therapeutics. The use of nanoporous silica-based materials as …
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal …
A mutant epidermal growth factor receptor (variously called ΔEGFR, de2–7 EGFR, or EGFRvIII)
containing a deletion of 267 amino acids of the extracellular domain is frequently highly …
containing a deletion of 267 amino acids of the extracellular domain is frequently highly …
Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury
Modulating the behaviors of reactive astrocytes is a potential therapeutic strategy for
neurodegenerative diseases. We found that upregulation and activation of the epidermal growth …
neurodegenerative diseases. We found that upregulation and activation of the epidermal growth …
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor (EGFR) but not wild-type …
RB Luwor, TG Johns, C Murone, HJS Huang… - Cancer research, 2001 - AACR
The monoclonal antibody (mAb) 806 was raised against the delta2–7 epidermal growth
factor receptor (de2–7 EGFR or EGFRvIII), a truncated version of the EGFR commonly …
factor receptor (de2–7 EGFR or EGFRvIII), a truncated version of the EGFR commonly …
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients
Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers
including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and …
including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and …